Biomarker evaluation in a randomized phase 2 study of MEHD7945A (MEHD) versus cetuximab (Cet) in ≥2 line recurrent/metastatic (R/M) squamous cell carcinomas of the head and neck (SCCHN) [MEHGAN]

被引：0
|
作者：
Pennel, Elicia [1 ]
Kapp, Amy V. [1 ]
Do, An [1 ]
Tam, Rachel [1 ]
Sumiyoshi, Teiko [1 ]
Marathe, Chaitra [1 ]
Sa, Susan [1 ]
Peale, Franklin [1 ]
Lackner, Mark [1 ]
Holden, Scott [1 ]
Seiwert, Tanguy [2 ]
Pirzkall, Andrea [1 ]
机构：
[1] Genentech Inc, San Francisco, CA 94080 USA
[2] Univ Chicago, Chicago, IL 60637 USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-1553
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1553
引用
收藏
页数：2
相关论文
共 50 条
  • [31] PREDICTORS OF EFFICACY IN THE EXTREME STUDY: CETUXIMAB PLUS PLATINUM-BASED THERAPY FIRST-LINE IN PATIENTS WITH RECURRENT AND/OR METASTATIC (R/M) SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)
    Vermorken, J. B.
    Mesia, R.
    Remenar, E.
    Erfan, J.
    Zabolotnyy, D.
    Benasso, M.
    Koralewski, P.
    Gross, A.
    Stroh, C.
    Bokemeyer, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 217 - 217
  • [32] Methotrexate plus or minus cetuximab as first-line treatment in a recurrent or metastatic (R/M) squamous cell carcinoma population of the head and neck (SCCHN), unfit for cisplatin combination treatment, a phase Ib-randomized phase II study Commence
    Ham, Janneke C.
    van Meerten, Esther
    Fiets, W. Edward
    Beerepoot, Laurens V.
    Jeurissen, Frank J. F.
    Slingerland, Marije
    Jonker, Marianne A.
    Husson, Olga
    van der Graaf, Winette T. A.
    van Herpen, Carla M. L.
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2020, 42 (05): : 828 - 838
  • [33] Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-na⟨ve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Ruzsa, A.
    Sen, M.
    Evans, M.
    Lee, L. W.
    Hideghety, K.
    Rottey, S.
    Klimak, P.
    Holeckova, P.
    Fayette, J.
    Csoszi, T.
    Erfan, J.
    Forssmann, U.
    Goddemeier, T.
    Bexon, A.
    Nutting, C.
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1278 - 1284
  • [34] Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-naïve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    A. Ruzsa
    M. Sen
    M. Evans
    L. W. Lee
    K. Hideghety
    S. Rottey
    P. Klimak
    P. Holeckova
    J. Fayette
    T. Csoszi
    J. Erfan
    U. Forssmann
    T. Goddemeier
    A. Bexon
    C. Nutting
    Investigational New Drugs, 2014, 32 : 1278 - 1284
  • [35] A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
    Fury, Matthew G.
    Sherman, Eric
    Lisa, Donna
    Agarwal, Neeraj
    Algazy, Kenneth
    Brockstein, Bruce
    Langer, Corey
    Lim, Dean
    Mehra, Ranee
    Rajan, Sandeep K.
    Korte, Susan
    Lipson, Brynna
    Yunus, Furhan
    Tanvetyanon, Tawee
    Smith-Marrone, Stephanie
    Ng, Kenneth
    Xiao, Han
    Hague, Sofia
    Pfister, David G.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2012, 10 (11): : 1391 - 1398
  • [36] Safety of the first-in-class anti-NKG2A monoclonal antibody monalizumab in combination with cetuximab: a phase Ib/II study in recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Cohen, Roger B.
    Salas, Sebastien
    Even, Caroline
    Kotecki, Nuria
    Jimeno, Antonio
    Soulie, Anne-Marie
    Tirouvanziam-Martin, Anne
    Zerbib, Robert
    Andre, Pascale
    Boyer-Chammard, Agnes
    Fayette, Jerome
    CANCER RESEARCH, 2017, 77
  • [37] A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study
    Seiwert, Tanguy Y.
    Kochanny, Sara
    Wood, Kevin
    Worden, Francis P.
    Adkins, Douglas
    Wade, James L.
    Sleckman, Bethany G.
    Anderson, Daniel
    Brisson, Ryan J.
    Karrison, Theodore
    Stadler, Walter M.
    Vokes, Everett E.
    CANCER, 2020, 126 (14) : 3237 - 3243
  • [38] Randomized, phase II study of ficlatuzumab with or without cetuximab in patients with pan-refractory, recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Bauman, Julie E.
    Roe, Denise
    Saba, Nabil F.
    Bauman, Jessica Ruth
    Kaczmar, John M.
    Burtness, Barbara
    Muzaffar, Jameel
    Julian, Ricklie Ann
    Wang, Steven
    Bearelly, Shethal
    Baker, Audrey
    Steuer, Conor Ernst
    Bhatia, Aarti K.
    Giri, Anshu
    Caulin, Carlos
    Stabile, Laura P.
    Centuori, Sara
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [39] Phase 2 study of dalantercept in recurrent or metastatic squamous cell carcinoma of the head and neck
    Jimeno, Antonio
    Posner, Marshall R.
    Weiss, Jared
    Wirth, Lori J.
    Saba, Nabil F.
    Cohen, Roger B.
    Popa, Elizabeta C.
    Argiris, Athanassios
    Grossmann, Kenneth F.
    Sukari, Ammar
    Korth, Chris
    Wilson, Dawn
    McClure, Ty
    Alimzhanov, Marat
    Pearsall, Scott
    Attie, Kenneth M.
    Sherman, Matthew L.
    Pandya, Shuchi Sumant
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [40] Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
    Hitt, R.
    Irigoyen, A.
    Nunez, J.
    Grau, J.
    Garcia Saenz, J.
    Pastor, M.
    Jara, C.
    Garcia Giron, C.
    Hidalgo, M.
    Cruz Hernandez, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345